This week, mega-cap earnings disappoint as investors ask “where’s the revenue”, US economy starts to show cracks and middle east conflict flares up (again)
BUY 6% Telix Pharma
Stocks closed higher for the sixth straight session Thursday, as fears of an economic slowdown were dispelled following stronger-than-expected labor market and retail sales data.
We recommend reallocating 2% of our portfolio from Elders (ELD) to Nufarm (GNC). This decision is based on the realization of a 9.2% profit in Elders and the assessment that Nufarm is currently undervalued, as supported by its recent earnings report and market conditions.
Stocks drifted higher driven by encouraging data showing a continued slowdown in inflation. This has raised expectations that the Federal Reserve might soon begin cutting interest rates, potentially as early as next month.
Stocks surged overnight as fresh evidence of easing inflation bolstered expectations for a Federal Reserve rate cut as early as next month, causing Treasury yields to drop.
Overall, Challenger’s financial results for FY2024 appear to have exceeded market expectations, particularly in terms of profitability and EPS growth, despite slightly lower total Life sales. The company’s performance has been recognized by an increased dividend and a positive outlook from most analysts.
Investors took a welcome breather to start the week as key inflation data is due over the next few days
Both bearish and bullish Investors were battered and bruised this week as the recovery in stocks continued following a major selloff earlier this week when concerns about an incoming recession took center stage and a recovery in the latter half of the week left us largely unchanged
This week, mega-cap earnings disappoint as investors ask “where’s the revenue”, US economy starts to show cracks and middle east conflict flares up (again)
This website provides general advice that does not take into account your individual objectives, financial situation, or needs. Past performance does not guarantee future results. The trade recommendations in our Pilot Portfolios are hypothetical, may exclude certain fees, and are not a basis for future investment decisions. Please do not rely solely on this information. We recommend seeking appropriate financial, taxation, and legal advice before making any investment decisions. Please refer to our Financial Services Guide for more information about our services.